SCHEMBL4237693

SCHEMBL4237693

O=c1c2ccccc2nc(-c2ccc(F)cc2)n1NCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.64
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
NPSR1 Q6W5P4 4/20 0.48
MAPT P10636 4/20 0.48
HTT P42858 3/20 0.48
LMNA P02545 2/20 0.48
HDAC6 Q9UBN7 1/20 0.46
HPGD P15428 2/20 0.46
GAA P10253 1/20 0.46
KDM4E B2RXH2 2/20 0.46
APP P05067 2/20 0.45
CFTR P13569 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233257 0.91 ALDH1A1 (0.53) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4233701 0.91 SMN1; SMN2 (0.63) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4233285 0.91 MAPT (0.55) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL13930051 0.88 SMN1; SMN2 (0.68) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4237651 0.87 SMN1; SMN2 (0.67) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4236185 0.87 SMN1; SMN2 (0.67) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4233689 0.87 SMN1; SMN2 (0.48) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4202602 0.85 SMN1; SMN2 (0.47) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4233248 0.85 ALDH1A1 (0.56) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4233215 0.84 SMN1; SMN2 (0.63) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 SMN1; SMN2 4767/4885CYP1A2 1598/4885CYP3A4 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.